ValiRx posts annual loss as R&D spending weighs
Cancer-focused biotechnology company ValiRx posted an full-year loss as R&D and other expenses weighed.
Pre-tax losses for the year through December amounted to £2.7m, compared...
Wed, 01/07/2020 - 08:45